Market cap
$1,155 Mln
Revenue (TTM)
$73 Mln
P/E Ratio
29.5
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
18.7
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
108,829,507
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viamet Pharmaceuticals Corp (VMET)
| -- | 15.2 | -12.4 | -- | -- | -- | -- |
|
BSE Sensex*
| -8.6 | 1.7 | 1.8 | -4.2 | 6.0 | 6.7 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viamet Pharmaceuticals Corp (VMET)
|
10.4 | 1,154.7 | 73.3 | 36.7 | 71.1 | 11.7 | 29.5 | 2.9 |
| 4.6 | 7.4 | 0.0 | -10.5 | -- | -130.8 | -- | 1.7 | |
| 40.6 | 10,433.6 | 5,371.0 | -169.0 | 8.0 | -1.8 | -- | 1.2 | |
| 10.9 | 923.4 | 207.6 | 52.2 | 41.3 | 30.6 | 17.9 | 4.8 | |
| 18.6 | 877.9 | 1,653.3 | 49.0 | 9.7 | 3.6 | 12.3 | 0.6 |
Shareholding Pattern
View DetailsAbout Viamet Pharmaceuticals Corp (VMET)
Versamet Royalties Corporation operates as metals royalty and streaming company, engages in the acquiring and managing royalties, streams, and other similar interests on metals and mining operations and projects in Peru, the United States, Africa,... and Canada. It explores for silver, gold, copper, graphite, lead, uranium, zinc, and molybdenum metals. Versamet Royalties Corporation was formerly known as Sandbox Royalties Corp. and changed its name to Versamet Royalties Corporation in June 2024. The company was incorporated in 2011 and is based in Vancouver, Canada. Read more
-
Chief Executive Officer & Director
Mr. Daniel O'Flaherty
-
Chief Executive Officer
Mr. Dan O'Flaherty
-
Headquarters
Vancouver, BC
-
Website
FAQs for Viamet Pharmaceuticals Corp (VMET)
What is the current share price of Viamet Pharmaceuticals Corp (VMET) Today?
The share price of Viamet Pharmaceuticals Corp (VMET) is $10.41 (NASDAQ) as of 26-Aug-2026 16:26 EDT. Viamet Pharmaceuticals Corp (VMET) has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Viamet Pharmaceuticals Corp (VMET)?
The P/E ratio of Viamet Pharmaceuticals Corp (VMET) is 29.47 times as on 21-Aug-2026.
The P/B ratio of Viamet Pharmaceuticals Corp (VMET) is 2.89 times as on 21-Aug-2026, a 67 premium to its peers’ median range of 1.73 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
2013 |
-- |
-- |
What is the 52 Week High and Low of Viamet Pharmaceuticals Corp (VMET)?
The 52-week high and low of Viamet Pharmaceuticals Corp (VMET) are Rs 15.00 and Rs 8.50 as of 27-Aug-2026.
What is the market cap of Viamet Pharmaceuticals Corp (VMET)?
Viamet Pharmaceuticals Corp (VMET) has a market capitalisation of $ 1,155 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Viamet Pharmaceuticals Corp (VMET)?
Before investing in Viamet Pharmaceuticals Corp (VMET), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.